Therapeutic guidelines antiretroviral treatment (ARV) of adult HIV infection, as of January 2011

Montaner, Julio. (Author). British Columbia Centre for Excellence in HIV/AIDS (Added Author). Canadian Electronic Library (Firm) (Added Author).

Summary: Deciding to start ART requires weighing the benefits of treatment on morbidity and mortality against its risks, including toxicity, resistance, drug interactions, and the costs and inconvenience of lifelong treatment. Sustained viral suppression restores and preserves immunologic function, decreasing opportunistic diseases and mortality. The patient must be ready and willing to adhere to lifelong therapy. Advances in ART continue to shift the therapeutic risk-benefit balance to earlier treatment. Improvements in potency, toxicity and tolerability, and pill burden allow for durable viral suppression for most patients.

Record details

Physical Description: electronic resource
remote
image/jpeg
image/jpeg
1 electronic text (48 p.) : digital file.
Publisher: Vancouver, B.C. : British Columbia Centre for Excellence in HIV/AIDS, [2011]

Content descriptions

General Note:	"Based on M Thompson, J Aberg, P Cahn, J Montaner, et al. Antiretroviral Treatment of Adult HIV Infection - 2010 Recommendations of the International AIDS Society-USA Panel. JAMA, July 21, 2010 - 304, (3) 321-333." Issued as part of the desLibris documents collection.
Bibliography, etc. Note:	Includes bibliographical references (p. 34-48).
Formatted Contents Note:	When to start -- What to start -- Monitoring -- When to change and what to change -- Conclusions -- References.
System Details Note:	Mode of access: World Wide Web.